All News

ACRmtg.jpg (keep)

Industry Abstract Previews - ACR2020

Jack Cush, MD

Each pharmaceutical company has spent months and years preparing to present and highlight their featured clinical trials and abstracts at ACR 2020.  This is our selection of their best studies for you to review and evaluate as part of your to-do list.

Read Article
RN.Laptop.jpg

ACR 2020 Your Way - Get Your Topic Emails

Jack Cush, MD

ACR is but a few days away; the question is: how will you tackle this virtual meeting? RheumNow has created several options for learning the way you want to. First is to feed your need. Are you a lupologist? A gout maven? A Spondylitis sleuth? A drug safety wannabe?

Read Article
pssfing.jpg

Abatacept in Early Systemic Sclerosis (ASSET study)

Jack Cush, MD

An open-label extension of the ASSET trial (abatacept in diffuse cutaneous systemic sclerosis) showed continued safety with significant improvements in the modified Rodnan Skin Score (mRSS) at 12 months, suggesting abatacept (ABA) may benefit early systemic sclerosis (SSc).

Read Article
PSS.hands_.Raynauds.jpg (keep)

FDA Invites Patient Input on Systemic Sclerosis Drug Development

Jack Cush, MD

While there have been several promising new agents for systemic sclerosis, many have failed - with all noting the difficulties in appropriate outcomes and endpoints for clinical trials. With this in mind, the FDA was interested in hearing patients’ perspectives on systemic sclerosis and new drug development, and held a virtual meeting on 10/13/20.

Read Article
Muscle (keep)

Immune Necrotizing Myopathy

Jack Cush, MD

A full read review of immune-mediated necrotizing myopathy is portrayed as a distinct subtype of inflammatory myopathies first described in 2004.

Read Article
podcast logo

RheumNow Podcast – Good Time Charlie…. (10.16.20)

Jack Cush, MD

Dr. Jack Cush sings the news and journal reports from the past week on RheumNow.com.

Read Article
podcast logo

RheumNow Podcast – Bad Disease & Bad Outcomes (10.9.20)

Jack Cush, MD

Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com.

Read Article
Beautiful poster and fascinating research from @chriswincup et al showing immune cellular iron deficiency in patients with #SLE. Time to add iron supplementation as part of standard #lupus therapy? https://t.co/Uf81KXbSM0 Abs#0294 #ACR20 @RheumNow https://t.co/z5SUjWFkdD

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
ANA antibodies in longitudinal #SLE cohort: - 759 patients - 84.8% remained ANA+ve during 5yr followup period - Pts w/ at least one -ve ANA in first 5yrs had milder disease (lower SLEDAI-2K, less steroid, fewer autoantibodies) Abs#0251 #ACR20 @RheumNow https://t.co/U7JbNpJA3w

Links:

Mrinalini Dey DrMiniDey ( View Tweet)

Dr. G Gilkeson #Klempererlecture #ACR20 @rheumnow There is a lupus gradient b/t Africa and US: we are seeing more SLE in the US (genetics? environmental? diet?)

k dao KDAO2011 ( View Tweet)

Dr. Gilkerson in 2F010- Lupus in Unusual Places at #ACR20- Is it environmental or genetics that explain differences between African and African-Amer populations? Study the population (Sierra Leone), but do so with cultural sensitivity. @RheumNow https://t.co/B1ikkQgCuk
Eric Dein ejdein1 ( View Tweet)
Do you routinely use septra/bactrim in SLE to prevent PCP/PJP? @RheumNow @CRASCRRheum

Janet Pope Janetbirdope ( View Tweet)

Review of 127 pts w/ diagnostic criteria for palindromic rheumatism - Most affected JTS were wrist, knee, MCP; 34% later developed CTD (28% RA, 2% lupus 3% other CTD). Progression predicted by +RF (HR 2.9), PIP (HR 2.4), Wrist (HR 2.5) & female (HR 2.2)

Dr. John Cush RheumNow ( View Tweet)

259 SLE patients followed an 80% were in lupus low disease activity state (LLDAS); 82% in remission; 19% w/ active dz. 56 pst in subjective Low activity (SLQ<6) compared to SLAQ>6, latter had more arthritis, fibromyalgia and took steroids https://t.co/IdeSNlaEOG

Links:

Dr. John Cush RheumNow ( View Tweet)

Observational study of 123 Spanish rheumatic dz pts w/ COVID-19, finds 54 hospitalized. Admitted pts were 69.7 yrs, and 22% died. Admission was assoc w/ older age, autoimmune dz (vs inflammatory arthritis; OR: 3.55), but not DMARD Rx. https://t.co/UWNyhOKbvF

Links:

Dr. John Cush RheumNow ( View Tweet)

The RheumNow Podcast is up - Bad Disease & Bad Outcomes. COVID consequences, TNFi Switching in SpA, psychosis in lupus? Watch it here> https://t.co/ced3cKg5eB or listent to podcast on iTunes> https://t.co/FHJv01AAbC or SoundCloud> https://t.co/e4nWr3wECz

Links:

Dr. John Cush RheumNow ( View Tweet)

Lockdown worsening; UK survey 678 patients musculoskeletal diseases pts in late April 2020 shows 53% worsening of Sx; 1/3 had clinic/hosp access probs problems & most (88%) had no probs w/ getting meds; but 44% needed others to help them get meds. https://t.co/3efmTdHhQx

Links:

Dr. John Cush RheumNow ( View Tweet)

Among 4766 mental health pts admited for Psychosis; 19% ANA tested and only 135 had a positive ANA >=1:160. (15% of those tested). Only 4 met 2019 ACR/EULAR criteria for SLE, and 2/4 met criteria for NPSLE. NPSLE prevalence was 1.5% in ANA+ psychosis Pts. https://t.co/c5C1VQaQAI

Links:

Dr. John Cush RheumNow ( View Tweet)

"Prednisone >30 mg/day for > 4 weeks, patients should be on PJP prophylaxis." Image shows when to start/stop PJP prophylaxis Dr. Kevin Winthrop on Risks/Prevention of OI @UTSWRheum Grand Rounds @rheumnow https://t.co/nXuWYRxbgy
k dao KDAO2011 ( View Tweet)
RheumNow Podcast is up! COVID effects on Rheum; drug approvals, Difficult RA, SLE complement & remission. Watch it here> https://t.co/490T6k1ytk or listen to the podcast on iTunes> https://t.co/FHJv01AAbC OR on souncloud> https://t.co/dAJ0827c3B

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×